Director	Title	Age	Since
Matthew Abernethy BRD	Director/Board Member	47	2022-10-31
Julie Boverie BRD	Director/Board Member	47	2023-04-18
Darin Lippoldt BRD	Director/Board Member	61	2022-10-31

More insiders

Diurnal Group plc is a specialty pharmaceutical company. It is focused on developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. It focuses on addressing unmet clinical and patient needs in hormone replacement by developing and marketing products for the rare and orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI). The Company's products include Alkindi and Efmody. Its product Alkindi (hydrocortisone granules in capsules for opening) is a specifically designed for young children suffering from paediatric AI, and the related condition CAH. Its product Efmody (modified-release hydrocortisone) provides a drug release profile that is designed to improve disease treatment for adults with CAH, as measured by androgen (male sex hormone) control. Its pipeline includes DNL-0200, DNL-0300, DNL-0400 and DNL-0500.

Employees

Sector

More about the company

01-21	Immedica Pharma AB completed the acquisition of Diurnal Group Limited from Neurocrine Biosciences, Inc..	CI
01-07	Immedica Pharma AB entered into a definitive agreement to acquire Diurnal Group Limited from Neurocrine Biosciences, Inc. for $65 million.	CI
25-08-06	Diurnal Group Limited Reports Earnings Results for the Full Year Ended December 31, 2024	CI
23-06-15	Diurnal Ltd. Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023	CI
22-11-02	Diurnal Shares Delisted After Neurocrine Biosciences Takeover	MT
22-11-01	Diurnal's Takeover Scheme By US-based Neurocrine Biosciences Becomes Effective	MT
22-10-31	Neurocrine Biosciences, Inc. completed the acquisition of Diurnal Group plc from Diurnal Directors, IP Group Plc, Polar Capital Holdings plc, Development Bank of Wales Plc, Amati Global Investors Ltd. and other shareholders.	CI
22-10-28	TRADING UPDATES: SulNOx, Marwyn loss widens; Kropz gets new facility	AN
22-10-28	Neurocrine's Acquisition of Diurnal Secures Court Approval	MT
22-10-21	TRADING UPDATES: Trackwise Designs wins deal; Cake Box names CFO	AN
22-10-21	Diurnal's Shareholders Approve Takeover Bid by Neurocrine	MT
22-10-20	UK shareholder meetings calendar - next 7 days	AN
22-10-07	Diurnal Group Wins Recommendation for Rare Genetic Disorder Drug in Wales	MT

22-09-14	Diurnal : Interim Results for the Twelve Months Ended 30 June 2022	PU
22-08-31	Form 8.3 - [Diurnal Group plc - 30 08 2022 - Opening Declaration] - (HHL)	AQ
22-08-31	SVM Asset Management - Form 8.3 - Diurnal Group plc	PR
22-08-30	IP Group PLC -Cash acquisition of portfolio company Diurnal	AQ
22-07-26	Diurnal : Trading Update	PU

Date	Insider	Type	Main position	Quantity	% Market Cap.
22-07-14	Stewart Jones	Free		22,400	0.0132%
22-07-14	John Porter	Free	Chief Technology Officer	30,500	0.0180%
22-07-14	Richard John Martin Ross	Free	Founder	26,892	0.0158%

DIUL GROUP Stock

Stocks

DNL

GB00BDB6Q760

Latest news : DIUL GROUP

Press Releases: DIUL GROUP

News in other languages: DIUL GROUP

Managers and Directors: DIUL GROUP

Latest insider transactions

Company Profile